Swati Kumari

Dr. Swati Kumari

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKSwati Kumari
Swati Kumari
RTReuben Kuruvilla Thomas
Reuben Kuruvilla Thomas
SSS. Sruthi
S. Sruthi
RBRamya Barani
Ramya Barani
SSS. Sangvi
S. Sangvi
Padma SrikanthPadma Srikanth
Padma Srikanth
A core component of every blood program is the supply of safe blood and blood products. The elevated risk of transmission through these products is due to parvovirus B19 (B19V) resistance to the virus inactivation procedures. Our study aimed to screen asymptomatic blood donors for B19V at a tertiary care hospital in Chennai, Tamil Nadu, between September 2020 and June 2021. Sera from 106 healthy blood donors who tested negative for Human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV), syphilis, and malaria were tested for anti-B19V IgM and IgG using a qualitative indirect enzyme-linked immunosorbent assay (ELISA). In the study population, 23.5% (n = 25) of donors tested IgM positive, 38.6% (n = 41) tested IgG positive, and 7.5% (n = 8) tested positive for both IgM and IgG. A proportion of 61.3% (n = 65) of the blood donors tested IgG negative, suggesting they had no past B19V infection. B19V DNA was not detected in any of the subjects. The high seroprevalence of IgM indicates that blood donors may have been recently exposed to B19V, potentially posing a risk to immunocompromised individuals and those with hematological stress. Further longitudinal studies with a larger sample size are recommended to better understand the risk of B19V transfusion transmission.

19 June 2024 in Heliyon
Verified
Journal Article
Open access
SKSwati Kumari
Swati Kumari
MBMarleena Banu
Marleena Banu
KRKrishnapriya Ramanatha
Krishnapriya Ramanatha
RBRamya Barani
Ramya Barani
KSKopula Sathyamurthy Sridharan
Kopula Sathyamurthy Sridharan
Burkholderia is a genus consisting of several species including the Burkholderia pseudomallei group, Burkholderia cepacia complex and other phytopathogens. Burkholderia species is a gram-negative bacillus with protean presentation that can be acquired from various sources, including water, soil, plant surfaces, and hospital environments. The organism on Gram staining is seen as gram-negative rod and on culture, the colonies are non-lactose fermenting. As it can mimic other diseases, it is frequently misdiagnosed and there is lack of awareness about the clinical spectrum of disease and diagnosis. This study aims to investigate varied clinical manifestations, identify potential risk factors and transmission modes and contribute to enhancing the clinical management of diseases. The increasing prevalence of Burkholderia infection implies its potential emergence as a significant public health concern, compounded by the growing incidence of diabetes, which has the potential to escalate the overall disease burden. The principal finding of the case series highlighted a spectrum of clinical presentations, emphasizing the need for comprehensive diagnostic strategies and tailored therapeutic interventions. These strategies will address the diverse manifestations and challenges posed by Burkholderia infections. This underscores the importance of heightened awareness among clinicians and microbiologists, given the need for extended treatment to achieve a complete cure and prevent potential relapses.

8 June 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
SKSwati Kumari
Swati Kumari
YMYamini Michelle Maran
Yamini Michelle Maran
KKKshitij A. Krishnan
Kshitij A. Krishnan
MRMahalakshmi Raja
Mahalakshmi Raja
GSGayatri S.
Gayatri S.
VPVinishaa Paraman
Vinishaa Paraman
Background: Digital Eye Strain (DES), also known as Computer Vision Syndrome (CVS), has become increasingly prevalent with the expansion of digital device use, particularly in academic settings. University students represent a high-risk group due to prolonged screen exposure. This study aimed to estimate the prevalence of DES using a validated instrument and to examine its association with screen time and related factors. Methodology: A cross-sectional analytical study was conducted among undergraduate students in Chennai, India, between January and March 2025. A structured questionnaire, including the validated Computer Vision Syndrome Questionnaire (CVS-Q), was administered using a non-probability convenience sampling approach through institutional academic groups. DES was defined as a CVS-Q score ≥6. Screen time was analyzed across all exposure categories. Descriptive statistics, non-parametric tests, and logistic regression analyses were performed. Results: Of all undergraduate students invited to participate in the study, 1,070 responded to the questionnaire. After excluding 24 incomplete responses, 1,046 participants were included in the final analysis (mean age 20 years; 61.8% female). Overall, 94.1% reported at least one symptom, and 73.7% met the criteria for DES (CVS-Q ≥6). Median CVS-Q scores increased progressively with screen time ( P < 0.001). Logistic regression analysis demonstrated a significant association between increasing screen time and DES ( P < 0.001). Female participants had significantly higher symptom scores ( P = 0.003). Increased screen time was also associated with higher odds of headache, with the highest risk observed in the >10 h group (OR = 6.53; 95% CI: 2.14–19.92; P = 0.001). Conclusion: DES is highly prevalent among undergraduate students and is associated with prolonged screen exposure and modifiable ergonomic factors, highlighting the need for structured preventive strategies, including digital hygiene awareness and ergonomic education within academic institutions, while representing a modifiable, lifestyle-associated health condition that aligns with SDG 3: Good Health and Wellbeing (Target 3.4), emphasizing prevention and promotion of wellbeing.

3 March 2025
Verified
Preprint
Open access
PDF file
SKSwati Kumari
Swati Kumari
This excellent manuscript effectively demonstrates the importance of integrating circulating tumor DNA (ctDNA) testing into existing follow-up strategies for HPV-positive head and neck squamous cell carcinoma (HNSCC). The study's microsimulation mode...

27 February 2026 in Annals of African Medicine
Verified
Journal Article
Closed access
MRMahalakshmi Raja
Mahalakshmi Raja
SAShreya Amoga
Shreya Amoga
SKSwati Kumari
Swati Kumari
Background: Hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is a DNA virus, composed of a nucleocapsid core and an outer envelope. It spreads through blood, needle-stick injuries, sexual contact, and vertical transmission from mother to child. The earliest marker of infection is hepatitis B surface antigen (HBsAg), detectable weeks before symptoms. According to the WHO, 254 million people lived with chronic HBV in 2022, with 1.2 million new infections annually. HBV causes serious liver complications, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Diagnosis relies on serological and molecular tests, such as the immunochromatographic test (ICT), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), and nucleic acid amplification testing (NAT). While ELISA, EIA, and NAT are highly sensitive but costly, ICT is a rapid, affordable, and valuable for screening; however, they carry a risk of false results compared to ELISA. Aim: The aim of this study was to evaluate and compare the diagnostic performance of rapid immunochromatographic test (ICT) with ELISA in HBsAg detection. Materials and Methods: A cross-sectional study was conducted from August 2024 to April 2025 in the Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Chennai. A total of 220 serum samples were included in the study. Each sample was tested for HBsAg using both rapid ICT and ELISA. Results were analyzed for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Cohen’s Kappa(κ) coefficient. Results: Of 220 samples, 42 (19.1%) were positive and 178 (80.9%) were negative by both methods. No false positives or false negatives were observed. ICT showed 100% sensitivity, specificity, PPV, and NPV, with Cohen’s κ = 1.0 ( P < 0.001), indicating perfect agreement with ELISA. Conclusion: ICT showed excellent diagnostic accuracy comparable to ELISA, supporting its use as a reliable and cost-effective screening tool in clinical and resource-limited settings. However, borderline results require confirmatory testing with ELISA or molecular methods. This study aligns with the United Nations Sustainable Development Goal 3: Good Health and Well-Being by supporting the development of affordable and accessible diagnostics for the elimination of viral hepatitis.

25 September 2026 in Biosensors
Verified
Journal Article
Open access
PDF file
TVTarika Devi Vijayaraj
Tarika Devi Vijayaraj
RRRakshitha K R
Rakshitha K R
SSSairam B. Subramaniam
Sairam B. Subramaniam
DADurgashini Annamalai
Durgashini Annamalai
SKSwati Kumari
Swati Kumari
Artificial intelligence (AI) is increasingly integrated with biosensors to improve signal processing, feature extraction, calibration, and clinical interpretation. However, analytical sensitivity and high internal validation accuracy do not necessarily translate into clinically useful or generalisable diagnostic performance. This review therefore reframes AI-enabled biosensing around clinical actionability rather than technological performance alone. We critically examine how AI can address signal noise, drift, matrix effects, and complex or high-dimensional biosensor outputs while evaluating how model selection should reflect data modality, dataset size, computational constraints, and intended deployment. Importantly, we distinguish the physical limit of detection (LoD) of the sensing system from algorithm-assisted effective detectability: AI cannot intrinsically lower the physical detection limit of a fixed transducer, but it can improve extraction and interpretation of weak signals near the noise floor. A central contribution of this review is a clinically actionable threshold framework that links representative biomarkers to decision-relevant concentration ranges, clarifying when further LoD reduction is clinically meaningful and when robustness, selectivity, dynamic range, calibration stability, and reproducibility matter more. We also critically appraise representative AI-enabled biosensor studies by sample size, validation strategy, reference standard, generalisability, interpretability, computational requirements, and evidence maturity, rather than headline accuracy alone. Across electrochemical, optical and spectroscopic, wearable, and point-of-care platforms, major translational barriers include biofouling, matrix interference, signal drift, dataset shift, insufficient external validation, privacy, and regulatory requirements. We conclude that progress in intelligent biosensing should be judged by reliable performance across clinically relevant ranges and demonstrated utility in real-world diagnostic workflows, rather than by progressively lower LoDs or isolated accuracy values alone.